Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine

被引:6
作者
Ford, Janet H. [1 ]
Ye, Wenyu [1 ]
Ayer, David W. [1 ]
Mi, Xiaojuan [2 ]
Bhandari, Swati [1 ]
Buse, Dawn C. [3 ]
Lipton, Richard B. [3 ,4 ]
机构
[1] Eli Lilly & Co, 893 Delaware St, Indianapolis, IN 46225 USA
[2] Tech Data Serv Co, King Of Prussia, PA USA
[3] Albert Einstein Coll Med, Dept Neurol, Bronx, NY USA
[4] Montefiore Med Ctr, Headache Ctr, Bronx, NY USA
关键词
Absenteeism; Non-work-related activity impairment; Chronic migraine; Episodic migraine; Meaningful change; Patient-reported outcome; Presenteeism; Validation; Work Productivity and Activity Impairment questionnaire (WPAI); Work productivity loss; OF-LIFE QUESTIONNAIRE; IRRITABLE-BOWEL-SYNDROME; PREVENTIVE TREATMENT; CONTENT VALIDITY; RESPONSIVENESS; REPRODUCIBILITY; RELIABILITY; OUTCOMES; MSQ;
D O I
10.1186/s41687-023-00552-4
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BackgroundNo available studies demonstrate validity and meaningful change thresholds of Work Productivity and Activity Impairment (WPAI) questionnaire in patients with migraine. In this post-hoc analysis, we assessed reliability, validity, responsiveness, and meaningful within-patient change from baseline to Month 3 for Work Productivity and Activity Impairment (WPAI) domain scores in patients with episodic migraine (EM) or chronic migraine (CM).MethodThe Phase 3, multicenter, randomized, double-blind, placebo-controlled CONQUER study (NCT03559257, N = 462) enrolled patients with EM or CM who failed two to four categories of prior preventive medication in past ten years. The analyses were performed for WPAI domain scores (absenteeism, presenteeism, overall work productivity, and non-work-related activity impairment). Migraine Specific Quality of Life Questionnaire version 2.1 (MSQv2.1) domain scores (Role Function-Restrictive [RFR] and Role Function-Preventive [RFP]), and monthly migraine headache days were used as anchors. Responder criteria were changes from baseline to Month 3 for each of these anchors and were defined as: increase in MSQ-RFR by >= 25.71 points and MSQ-RFP by >= 20.00 points and a 50% reduction in monthly migraine headache days. Assessments were performed for overall population, and patients with EM or CM. The meaningful change threshold was determined based on Youden index, Phi coefficient and sensitivity.ResultsOf 462 randomized patients, 444 who completed WPAI questionnaire were included in post-hoc analysis. Test-retest reliability over 3 months in a stable subgroup revealed moderate correlations for non-work-related Activity Impairment (ICC = 0.446) presenteeism (ICC = 0.438) and a fair correlation for overall work productivity loss (ICC = 0.360). At baseline, all correlations between WPAI domain scores and continuous anchor variables exceeded recommended threshold of >= 0.30, except for WPAI domain scores with number of monthly migraine headache days. Patients achieving pre-specified responsiveness thresholds for monthly migraine headache days, and MSQ-RFP, MSQ-RFR from baseline to Month 3 (responders) showed significant improvements in WPAI domain scores compared with non-responders (P < 0.001). The meaningful change thresholds of -20 (% unit) were identified for WPAI domain scores.ConclusionIn conclusion, WPAI has sufficient validity, reliability, responsiveness, and appropriate interpretation standards to assess the impact of EM or CM on presenteeism and overall work productivity loss and non-work-related activity impairment.
引用
收藏
页数:15
相关论文
共 54 条
[1]  
[Anonymous], 2018, EMGALITY (galcanezumab-gnlm) [package insert]
[2]  
[Anonymous], QULIPTA ATOGEPANT PR
[3]  
[Anonymous], 2019, VALUE HLTH REGION IS, DOI DOI 10.1016/J.VHRI.2019.08.342
[4]   Validating Migraine-Specific Quality of Life Questionnaire v2.1 in Episodic and Chronic Migraine [J].
Bagley, Christine L. ;
Rendas-Baum, Regina ;
Maglinte, Gregory A. ;
Yang, Min ;
Varon, Sepideh F. ;
Lee, Jeff ;
Kosinski, Mark .
HEADACHE, 2012, 52 (03) :409-421
[5]   Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine [J].
Blumenfeld, Andrew M. ;
Patel, Atul T. ;
Turner, Ira M. ;
Mullin, Kathleen B. ;
Manack Adams, Aubrey ;
Rothrock, John F. .
JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH, 2020, 11
[6]   The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response [J].
Brandes, Jan Lewis ;
Diener, Hans-Christoph ;
Dolezil, David ;
Freeman, Marshall C. ;
McAllister, Peter J. ;
Winner, Paul ;
Klatt, Jan ;
Cheng, Sunfa ;
Zhang, Feng ;
Wen, Shihua ;
Ritter, Shannon ;
Lenz, Robert A. ;
Mikol, Daniel D. .
CEPHALALGIA, 2020, 40 (01) :28-38
[7]   Validation of electronic data capture of the irritable bowel syndrome - Quality of life measure, the work productivity and activity impairment questionnaire for irritable bowel syndrome and the EuroQol [J].
Bushnell, DM ;
Reilly, MC ;
Galani, C ;
Martin, ML ;
Ricci, JF ;
Patrick, DL ;
McBurney, CR .
VALUE IN HEALTH, 2006, 9 (02) :98-105
[8]   Proposed new diagnostic criteria for chronic migraine [J].
Chalmer, Mona Ameri ;
Hansen, Thomas Folkmann ;
Lebedeva, Elena R. ;
Dodick, David W. ;
Lipton, Richard B. ;
Olesen, Jes .
CEPHALALGIA, 2020, 40 (04) :399-406
[9]   Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment [J].
Cole, Jason C. ;
Lin, Peggy ;
Rupnow, Marcia F. T. .
QUALITY OF LIFE RESEARCH, 2007, 16 (07) :1231-1237
[10]   REPRODUCIBILITY AND RESPONSIVENESS OF HEALTH-STATUS MEASURES - STATISTICS AND STRATEGIES FOR EVALUATION [J].
DEYO, RA ;
DIEHR, P ;
PATRICK, DL .
CONTROLLED CLINICAL TRIALS, 1991, 12 (04) :S142-S158